Stachon Axel, Segbers Elmar, Holland-Letz Tim, Kempf Reiner, Hering Steffen, Krieg Michael
Institute of Clinical Chemistry, Transfusion and Laboratory Medicine, BG-University Hospital Bergmannsheil, Buerkle de la Camp-Platz 1, Ruhr-University Bochum, 44789 Bochum, Germany.
Crit Care. 2007;11(3):R62. doi: 10.1186/cc5932.
In critically ill patients, the appearance of nucleated red blood cells (NRBCs) in blood is associated with a variety of severe diseases. Generally, when NRBCs are detected in the patients' blood, the prognosis is poor.
In a prospective study, the detection of NRBCs was used for a daily monitoring of 383 medical intensive care patients.
The incidence of NRBCs in medical intensive care patients was 17.5% (67/383). The mortality of NRBC-positive patients was 50.7% (34/67); this was significantly higher (p < 0.001) than the mortality of NRBC-negative patients (9.8%, 31/316). Mortality increased with increasing NRBC concentration. Seventy-eight point six percent of the patients with NRBCs of more than 200/microl died. The detection of NRBCs is highly predictive of death, the odds ratio after adjustment for other laboratory and clinical prognostic indicators being 1.987 (p < 0.01) for each increase in the NRBC category (0/microl, 1 to 100/microl, 101 to 200/microl, and more than 200/microl). Each step-up in the NRBC category increased the mortality risk as much as an increase in APACHE II (Acute Physiology and Chronic Health Evaluation II) score of approximately 4 points. The mortality of patients who were NRBC-positive on the day of relocation from the intensive care unit to a peripheral ward was 27.6% (8/27). This was significantly higher than the mortality of patients who were NRBC-negative on the relocation day (8.6%, 28/325; p < 0.01). On average, NRBCs were detected for the first time 14 days (median, 3 days) before death.
The routine analysis of NRBCs in blood is of high prognostic power with regard to mortality of critically ill patients. Therefore, this parameter may serve as a daily indicator of patients at high mortality risk. Furthermore, NRBC-positive intensive care patients should not be relocated to a normal ward but should obtain ongoing intensive care treatment.
在重症患者中,血液中出现有核红细胞(NRBCs)与多种严重疾病相关。一般来说,当在患者血液中检测到NRBCs时,预后较差。
在一项前瞻性研究中,对383名内科重症监护患者进行每日NRBCs检测以进行监测。
内科重症监护患者中NRBCs的发生率为17.5%(67/383)。NRBCs阳性患者的死亡率为50.7%(34/67);这显著高于NRBCs阴性患者的死亡率(9.8%,31/316;p<0.001)。死亡率随NRBCs浓度增加而升高。NRBCs超过200/微升的患者中有78.6%死亡。NRBCs的检测对死亡具有高度预测性,在调整其他实验室和临床预后指标后,NRBCs类别每增加一级(0/微升、1至100/微升、101至200/微升、超过200/微升),优势比为1.987(p<0.01)。NRBCs类别每上升一级,死亡风险增加幅度与急性生理与慢性健康状况评分系统II(APACHE II)评分增加约4分相当。从重症监护病房转至普通病房当天NRBCs阳性患者的死亡率为27.6%(8/27)。这显著高于转科当天NRBCs阴性患者的死亡率(8.6%,28/325;p<0.01)。平均而言,NRBCs首次检测到的时间在死亡前14天(中位数为3天)。
血液中NRBCs的常规分析对重症患者的死亡率具有很高的预后评估价值。因此,该参数可作为高死亡风险患者的日常指标之一。此外,NRBCs阳性的重症监护患者不应转至普通病房,而应继续接受重症监护治疗。